Ligand Pharmaceuticals Inc SEC filings LGNZZ
Ligand Pharmaceuticals Inc has 1,000 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 18, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| DEF 14A | Proxy statement | Apr 21, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 22, 2025 | — |
| DEF 14A | Proxy statement | Apr 22, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Jun 3, 2024 | — |
| DEFA14A | Additional proxy material | May 9, 2024 | — |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 20, 2023 | — |
| DEF 14A | Proxy statement | Apr 20, 2023 | — |
| DEFA14A | Additional proxy material | Apr 22, 2022 | — |
| DEF 14A | Proxy statement | Apr 22, 2022 | Jun 10, 2022 |
| DEFA14A | Additional proxy material | May 18, 2021 | — |
| DEFA14A | Additional proxy material | Apr 23, 2021 | — |
| DEF 14A | Proxy statement | Apr 23, 2021 | Jun 4, 2021 |
| DEF 14A | Proxy statement | Nov 12, 2020 | Dec 15, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2020 | Dec 15, 2020 |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Apr 24, 2020 |
| DEFA14A | Additional proxy material | Jun 4, 2019 | — |
| DEFA14A | Additional proxy material | Apr 24, 2019 | — |
| DEF 14A | Proxy statement | Apr 24, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Jun 4, 2018 | — |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Apr 27, 2018 |
| DEF 14A | Proxy statement | Apr 14, 2017 | Apr 14, 2017 |
| DEFA14A | Additional proxy material | Apr 14, 2017 | — |
| DEFA14A | Additional proxy material | Apr 12, 2016 | — |
| DEF 14A | Proxy statement | Apr 12, 2016 | Apr 12, 2016 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGND (Nasdaq), LGNDZ (OTC), LGNXZ (OTC), LGNYZ (OTC), LGNZZ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 886163
- Former names
- LIGAND PHARMACEUTICALS (until Sep 13, 1994)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.